Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) the same day to discuss results and provide a business update. The call will be accessible via phone and webcast, with both live and replay options available.

JUPITER, Fla.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.

Conference Call and Webcast Information

Date:			Thursday, November 7, 2024
Time:			8:30 a.m. ET (5:30 a.m. PT)
Conference Call:			(888) 596-4144 (U.S. & Canada)
			(646) 968-2525 (International)
			Conference ID is 8755336
Webcast:			Live and replay webcasts of the call are available here.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241023964788/en/

Investors:

Melanie Herman

investors@ligand.com

(858) 550-7761

LifeSci Advisors

Bob Yedid

bob@lifesciadvisors.com

(516) 428-8577

Media:

Kellie Walsh

media@ligand.com

(914) 315-6072

Source: Ligand Pharmaceuticals Incorporated

FAQ

When will Ligand (LGND) report Q3 2024 earnings?

Ligand (LGND) will report its third quarter 2024 financial results before market open on Thursday, November 7, 2024.

What time is Ligand's (LGND) Q3 2024 earnings call?

Ligand's Q3 2024 earnings conference call is scheduled for Thursday, November 7, 2024, at 8:30 a.m. ET (5:30 a.m. PT).

How can I access Ligand's (LGND) Q3 2024 earnings call?

The earnings call can be accessed via phone at (888) 596-4144 (U.S. & Canada) or (646) 968-2525 (International) using Conference ID 8755336, or through a live webcast available on the company's website.